- Home
- ARVN vs NIE Comparison
ARVN vs NIE Comparison
Compare ARVN & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | NIE |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 655.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | NIE |
|---|---|---|
| Price | $10.92 | $25.09 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 781.8K | 78.4K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.04% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $20.11 |
| 52 Week High | $14.22 | $26.00 |
Technical Indicators
Market Signals| Indicator | ARVN | NIE |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 62.91 |
| Support Level | $9.02 | $24.75 |
| Resistance Level | $12.43 | $25.62 |
| Average True Range (ATR) | 0.63 | 0.42 |
| MACD | 0.07 | 0.24 |
| Stochastic Oscillator | 44.71 | 88.86 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.